Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel polymer micelles + cisplatin + immune checkpoint inhibitor as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma
ChiCTR2600134839Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel and cisplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Objective response rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600134839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134839.